We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nymox Pharmaceutical’s investigational treatment for enlarged prostate failed to meet primary endpoints in two Phase III tests, after posting stronger results in previous trials.